IPT, Vitamin C and QOL

8/3/2019 IPT, Vitamin C and QOL

1/122

IPT, Vit C and QOL

2nd Annual RiordanIVC and Cancer Symposium

October 8 & 9, 2010

Bradford S. Weeks, M.D.

www.weeksmd.com [email protected]


2/122

BSW (c) 2010

GOALS for this Presentation

1) understand the role of insulin inpotentiating chemotherapeutic benefits

2) understand the theoretical and practicalaspects of Corrective Cancer Care (including Insulin Potentiation Therapy)

3) begin to incorporate side -effect freechemotherapy in your clinical practice.


3/122

BSW (c) 2010

Disclaimer:

no commercial interestor

conflict of interest declared


4/122

BSW (c) 2010

A Common Understanding of a DOG


5/122

BSW (c) 2010

RORY


6/122

BSW (c) 2010

New Puppy Syndrome


7/122

BSW (c) 2010

Rory really enjoying acar ride with Amelia


8/122

BSW (c) 2010

Corrective Medicine and Psychiatry
http://../


9/122

BSW (c) 2010

Thanks

and Congratulations!


10/122

BSW (c) 2010 Tenzin Choedrak

Abram Hoffer Hugh Riordan David Horrobin

Otto Wolff Rudolf Steiner


11/122

BSW (c) 2010

"A physician once told me that nothing arouses somuch bitter enmity and heated arguments among hiscolleagues, as the subject of cancer. This may be dueto the guilty recollections of cancer victims expiringwho might have been saved; or of the memories of patients pronounced hopelessly ill who recovered

under the treatment of a 'quack,' or whomiraculously lived without further treatment.

Possibly these guilt reactions and the remorse overexhausting the money of patients and their relatives

in futile cancer treatments, account for some of thesepsychological manifestations which are expressed inhostility and attack."

Nat Morris (written in 1958)


12/122

BSW (c) 2010

Even Bill Gates took some risks in life


13/122

BSW (c) 2010

Its not so important whether

you win or lose but rather,how you play the game.

My goal is to improvethe quality and quantity

of your life.


14/122

BSW (c) 2010

The Role of Hope

There are no incurable illnesses,

only incurable people.

Paracelsus(1433-1541)


15/122

BSW (c) 2010

Insulin Potentiation Therapy forthe Treatment of (people with)

Cancer

Part 1:The History and Rationale


16/122

BSW (c) 2010

On July 27, 1921, Canadian scientists Frederick

Banting and Charles Best first isolated insulin andwithin a year, the first human sufferers of diabetes were receiving insulin treatments.

Lilly began manufacturing large doses of purifiedinsulin in November 1922.

In 1926, Donato Perez Garcia had 10 units of

insulin injected intravenously."


17/122

BSW (c) 2010

The Development of the IPT Concept

Donato Perez Garcia, Sr., MD (1896 - 1971) first conceived of the therapy in Mexico City in 1926 and named it CellularTherapy to Change the Biophysical Biochemical Constantsof the Blood. Treated infectious illnesses: malaria, syphilisand poliomyelitis before focusing on cancer.

His son, Donato Perez Garcia y Bellon, MD (1930 - 2000) andand grandson - Donato Perez Garcia, Jr., MD (1957 - )followed in his footsteps.

Steven Ayre, MD learned about the therapy in 1975 andbecame the teacher of American doctors.

Bradford Weeks, M.D. learned IPT in 2001 from Dr. Ayreand is a certified clinical instructor in IPT for doctorswishing to learn this methodology.


18/122

BSW (c) 2010

From the book, Terapia Celular or Cellular Cancer Therapy through Modification of Blood Physico-Chemical Constants or

Donatian Therapy - written by Donato I & II:

According to Terapia Celullar, an animalstudy with dogs was done in 1930 to testabsorption of anti-syphilis drugs, namely

mercury and NeosalvarsanPrior to this, the doctor had given himself

intramuscular injections.


19/122

BSW (c) 2010

A human study with neurosyphillis patients wasconducted in Austin State Hospital in 1937, theresults of which are discussed in a letter by Dr.

Garcia dated September 1937.

On April 10, 1944, TIME magazine published anarticle on Dr. Garcia's "Insulin Shock Therapy,"in which a visit to the San Diego Naval Hospital isdiscussed, where Dr. Garcia treated malaria and

rheumatic fever patients.

Wed like him to come back and do it again.


20/122

BSW (c) 2010

According to the timelinewritten by Dr. Donato,

"January 1946 - First breastcancer patient successfully

treated using IPT."


21/122

BSW (c) 2010

Find a cure

before I grow

boobs!


22/122

BSW (c) 2010

Conventional Chemotherapy

Pros:Powerful drugsEffective at killing cancer

Cons: Powerful drugsEffective at killing patients while killing cancer cellsCost (average oncologist mark up = 400%)Effectiveness rate = 2.1% (!!!)


23/122

BSW (c) 2010

Problems with Conventional Chemotherapy1) Adequate intra-cellular concentrations requires

high dose, systemic administration of these drugs.

2) Lack of tissue specificity for drugs.

3) Consequence: Multiple tissue and organ toxicity(side-effects).

4) Note the tragic and little reported facts that 1)chemotherapy and radiation do NOT kill stemcells and 2) 99% of the cells in a cancerous tumorare NON-cancerous


24/122

BSW (c) 2010

FACT: ~ 2% of all cancers respond to chemotherapy (!!!??)

FACT: Conventional Chemotherapy hurts more than it helps.

OPINION: The overall contribution of curative and adjuvant cyto - toxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA . . . chemotherapy only makes a minor contribution to cancer survival.To justify the continued funding and availability of drugs used in

cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.

Morgan G, Ward R, Barton M. in his article:The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.See Clin Oncol (R Coll Radiol). 2004 Dec;16(8):549-60.)


25/122

BSW (c) 2010

Why Do Cancer Cells Resist Chemotherapy?

1. resistant cells survive and reproduce survival of the fittest;2. cancer cells mutate and replicate3. gene amplification: hundreds of copies of genes which produce chemo-

inactivating proteins (inc. MDR gene expression).4. P-glycoprotein pump which pumps drug out of cells (inc. MDR expression).5. cancer cells inactivate the pump which brings the drugs into the cells (e.g.

decreased expression folate transporter with MTX).6. cancer cells learn to repair DNA damage caused by some chemo drugs

(inc. nucleoside excision repair with alkylating agents and platinum drugs;inc. O alkyl-guanine alkyl transferase with nitrosureas, procarbazine, andtemozolamide).

7. cancer cells learn to inactivate chemo drugs or decrease their activation(decreased folypolyglutamyl synthetase with MTX or decreaseddeoxycytidine kinase with cytosine arabinoside, fludarabine phosphate, andcladrabine).

8. increased detoxification (increased glutathione or GSH tranferase)


26/122

BSW (c) 2010

What would be the Elements of an IdealSolution to this Chemotherapy Dilemma ?

1) To develop a method of differentiating the cancer cellpopulation from the normal cell population.

2) To deliver lowered doses of drug more specificallyinto this differentiated cancer cell population.

3) To maintain and /or enhance chemotherapys cell -killing effectiveness in cancer cells.

4) To reduce / avoid chemo side effects in normal cells.


27/122

BSW (c) 2010

Which box are you thinking outside of?


28/122

BSW (c) 2010

Insulin Potentiation Therapy

Utilizes Insulin to Modify EndogenousMechanisms of Malignancy

Selectively Targets Cancer CellsEnhances Anti-cancer Drug EffectsVery Low Doses of Chemotherapeutic Agents

Almost Completely Eliminates Dose RelatedSide Effects.


29/122

BSW (c) 2010

Insulin Receptors (IRs) & Cancer Cells

# of IRs on cancer cells is much greater than nl cells

IR count correlates with tumor size and histological

grading.

The binding capacity and affinity for 125-I labeledinsulin was found to be 9 times as great in breastcancer cells than normal cells.

IRs do not down regulate as readily and can have1000 fold resistance to receptor down-regulation.


30/122

BSW (c) 2010

Mammals have 100 to 100,000insulin receptors per cell.

Cancer cells have from 6 to 17

times more IRs per cell thannon-cancer cells .


31/122

BSW (c) 2010

Insulin & Cancer Cells

1) Insulin stimulates cell replication.

2) Insulin is produced by cancer cells (i.e. biopsyspecimens produce insulin)

3) Cytoplasmic B-subunit of Insulin has tyrosine

kinase activity (oncogene product)

4) insulin resistance increases cancer risk.


32/122

BSW (c) 2010

Elevated IGF levels

Hodgkins & Non -Hodgkins Lymphoma Renal AdenocarcinomaCervical & Uterine Carcinoma

Breast, Colon, and Lung CarcinomaLymphoblastic leukemiaAmount of IGFs correlates with stageCancer cells have up to 10 times more IGF receptors

on their surfaces.Treatment causes the IGF levels to decrease.


33/122

BSW (c) 2010

Insulin and IGF-1 operate autonomouslyat the cellular level within tumors topromote tumor growth.

IGF-1 is the major anabolic hormonewhile insulin regulates and provides

the fuel for these processes.


34/122

BSW (c) 2010

Rapidly growing tumors are more sensitive tochemotherapy than slow-growing tumors.

Studies at George Washington University,National Cancer Institute and

M.D. Anderson Hospital & Tumor Institutetested and proved that insulin doespotentiate the effects of chemotherapy.


35/122

BSW (c) 2010

Hence, the results of our experimentsindicate that tumor-specific growthstimulatory hormones can be utilized toovercome the cyto-kinetic drug resistance.thereby render subpopulations of tumor

cells vulnerable to the lethal effects of cellcycle-active drugs that otherwise wouldhave remained inert to their effects and

might have constituted a potential source of late treatment failure.


36/122

BSW (c) 2010

After IV Insulin:

Membrane EffectImproved drug penetration into cancer cellsUse lower doses to reduce side effectsShorten treatment cycle intervals

Metabolic EffectIncreased proportion in S phase.Increase rate of cell kill per cycle

Cellular Differentiation EffectExcess IR & IGF-R on cancer cellsSpecifically targets cancer smart bomb Relative sparing of normal tissue from toxicity


37/122

BSW (c) 2010

In vitro, after adding insulinto an asynchronouspopulation of breast cancer

cells, the S phase fractionwas 66% compared to only

37% in the controls.


38/122

BSW (c) 2010

From Treating Cancer with Insulin Potentiation Therapy p 84by Ross Hauser, M.D. 2002 Pub: Beulah Land Press


39/122

BSW (c) 2010

Insulin and Appetite

IPT changes the pathophysiology of thefatigued, depressed and anorexic patient.

Insulin stimulates appetiteResults in weight gainProduces euphoria


40/122

BSW (c) 2010

Human breast cancer cells have

six times more insulin receptors (1) and ten times more IGF-I receptors(2) than normal tissues in the body.

1) Holdaway IM, Freisen HG. Hormone binding by humanmammary carcinoma. Cancer Res 37:1946-1952, 1977

2) Cullen JK et al. IGF-I receptor expression and functionin HBCC. Cancer Res 50:48-53, 1990


41/122

BSW (c) 2010

Insulin enhanced the cytotoxiceffect of methotrexate in MCF-7human breast cancer cells in vitro

by a factor of up to ten thousand.(that is 10,000 fold )

Alabaster O, Vonderhaar BK Shafie SM. Metabolic modification byinsulin enhances methotrexate cytotoxicity in MCF-7 human breastcancer cells. Eur J Cancer Clin Oncol 17:1097-1103, 1981


42/122

BSW (c) 2010

Preincubation of MDA-MB-231human breast cancer cells in vitrowith insulin resulted in an increased

intracellular accumulation of ellipticine with a concomitantincrease in cytotoxicity.

Oster JB, Creasey WA. Enhancement of cellular uptake of ellipticine byinsulin preincubation. Eur J Cancer Clin Oncol 1981, 17:1097-1103

Pretreatment with insulin enhances anticancer


43/122

BSW (c) 2010

Pretreatment with insulin enhances anticancerfunctions of 5-fluorouracil in humanesophageal and colonic cancer cells

Ke ZOU1,2, Ji-hang JU1,2, Hong XIE1

Conclusion: These data suggest that insulinenhances anticancer functions of 5-FU whenit is treated before 5-FU for the appropriatetime in human esophageal and coloniccancer cell lines.

PUB Acta Pharmacol Sin 2007 May; 28 (5): 721 730 2007

The effect of insulin on chemotherapeutic


44/122

BSW (c) 2010

The effect of insulin on chemotherapeuticdrug sensitivity in human esophageal and

lung cancer cellsJIAO Shun-Chang, HUANG Jing,

Conclusion As a reversible metabolic promoter,insulin enhances the cytotoxity of the

chemotherapeutic agents . It is possible to increasethe growth and metabolism of cancer cells first, inorder to enhance the chemosensibility, and thenadminister chemotherapeutic agents, thus

improving their therapeutic effects.

PUB: Natl Med J China, February 10, 2003; Vol 83, No 3, Page 195-197.


45/122

BSW (c) 2010

Insulin fuels Cancer

Cancer cells eat glucoseCancer cells have 6x > insulin receptorsInsulin allows greater membrane permeabilityfor glucoseCancer cells have 10x > IGF-1 receptorsIGF-1 increases S phase (growth phase)

Synergetic membrane & metabolic effectElegant medicine: think PO vs. IV ABX


46/122

BSW (c) 2010

Summary: Biochemistry of Insulin and Cancer

Glucose is the ONLY fuel cancer cells can useCancer cells have 6 to 17x > IRs than regular cellsCancer cells have 10 x > IGF-1 Rs than regular cells

INS+IR increases delta-9-desaturase which makescancer cells become permeableIGF-1 doubles number of cancer cells in S-phase;

increasing vulnerability to chemotherapy drugs

Cancer cells are selectively targeted so lower doses of chemo drugs preserves immune function

Appetite improves, weight and euphoria increase


47/122

IPT is a chemotherapy-based protocol usinginsulin as a biologic response modifier of theendogenous mechanisms of malignancy.

In IPT, insulin is used to selectively targetcancer cells with lowered doses of chemotherapydrugs, enhancing drug effects on these cells and,

at the same time, effectively reducing dose-related chemotherapy side effects on host normaltissues.

Insulin Potentiation Therapy


48/122

BSW (c) 2010

The Nature of Cancer

1) Aggressive or not?2) Curable or not?

3) Infectious or not?4) What is the role of mind/body?


49/122

BSW (c) 2010

The Mechanisms of Malignancy

The combination of insulin andIGF-I operates autonomously at thecellular level within tumors, and thisoperation is free from any higherlevel of integrated control


50/122

BSW (c) 2010

The Mechanisms of Malignancy (cont.)

The two work together in an autocrine and/orparacrine manner and in a complementaryfashion, with IGF-I being the major anabolic

hormone responsible for mediating messagesabout growth in the tumor, while insulinregulates and provides the fuel for theseprocesses.

Zapf J., Froesch E.R. Insulin-like growth factors/somatomedins:structure, secretion, biological actions and physiological role. Hormone

Res 24:121-130, 1986.


51/122

BSW (c) 2010

Nature abhors a vacuum.

Empty or unfilled spaces areunnatural as they go against the

laws of nature and physics.


52/122

BSW (c) 2010

Cancer is not the problem.

Cancer is an adaptive responseto the problem.

Toxic blood and tissue is theProblem

Every town has a garbage dump.Solution: make less trash, recycle.

To avoid cancer: eat non-toxic foods and eat less!


53/122

BSW (c) 2010

Removing the tumor is the leastimportant step in curing cancer.


54/122

BSW (c) 2010

The Three Steps

1) Take down cancer welcome sign2) Enhance immune system3) Reduce or kill cancer cells

Metaphor:Bailing a sinking boat vs. plugging the hole
http://../


55/122

BSW (c) 2010

The Four Bodies

TheViolin Concert
http://../


56/122

BSW (c) 2010

Corrective Cancer Care

The Health PyramidThe NETNutritionExerciseThought

LIFESTYLE FACTORS (85%)

Repair the NET Nutrition (get it) Exercise (use it) Thoughts (manage it)

Supplementand / or

Detoxify

Drugs Surgery

Hospital


57/122

BSW (c) 2010

Nutrition

What comes in all 7 sensesQuality organic freshAdequate proteinHaelan 951Supplements:

MVMMSoul food


58/122

BSW (c) 2010

Supplements

Prevent cancer cells from repairing themselves (caffeine)Force apoptosis (curcumin, tumeric)Support immune system

1. Theanine (increases interferon gamma)

2. Arginine (increases NKC and T-cell function)3. American ginseng (increases T-cell function)4. Melatonin (increases IL-2, epidermal growth factor)5. Avemar (increases T-cell function)6. Vitamin C and others

Prevent Metastases - Modified Citrus Pectin, Heparin,Thalidomide.

All of the above and more: Haelan 951


59/122

BSW (c) 2010

Haelan 951

a raw, fermented, organic, non-GMO, whole soyproduct

This product contains all 5 of the super foodsdiscovered in 1991 by the National Cancerinstitute after their $20 million study searchingfor anti-cancer properties in fruits and vegetables:1) Isoflavones 2) Protease Inhibitors 3) Saponins4) Phytosterols 5) Phytic Acid Compounds

(Journal of the National Cancer Institute April 17,1991)


60/122

BSW (c) 2010

Haelan 915 Benefits

1) Apoptosis is stimulated:

Clinical Implication: Apoptosis is the healthy,

appropriate cells death which occurs at the righttimes after a cell has lived it full normal life. Incontrast, cancer cells resist apoptosis and liveeternally thereby killing the cancer patient.


61/122

BSW (c) 2010

Haelan 915 Benefits (cont.)

2) DNA Repair is enhanced.Clinical Implication: DNA damage is the hallmarkof cancer. If DNA is repaired a cell can stop being

cancerous.

3) Reactivates P-53 Tumor Suppressor GeneClinical Implication: This raises levels of P-21 inbreast, ovarian and prostate cancer cell andthereby suppresses cancer and allows apoptosis.


62/122

BSW (c) 2010

Haelan 915 Benefits (cont.)4)P21 gene activity is increased

Clinical Implication: This lifesaving gene isderived from the anti-cancer gene P53 and allowsto cancer call death

5) Anti-angiogenesisClinical Implication: Angiogenesis is the creationof a blood supply to tissues low in oxygen. Withoutthis new blood supply, cancer cells can not grow.Avastin stops angiogenesis by destroying VEGF(vascular endothelial growth factor) systemicallywhich is fatal. Haelan 951 stops angiogenesiswithout destroying VEGF.


63/122

BSW (c) 2010


6) Reduces exosomesClinical Implication: These are particles thatinhibit immune defense against cancer, they

inhibit both NK cell function and gammainterferon.7) Increases BAX 500% compared with the drug

Doxorubicin (in cases of breast cancer)

Clinical Implication: This is a gene which killscancer cells via allowing apoptosis.


64/122

BSW (c) 2010


8) Decreases BCL2 200% - in comparison toDoxorubicin (in cases of breast cancer)Clinical Implication: This is a gene which allows

cancer cells to thrive by evading apoptosis.

9) Improves Anti-apoptotic Ratio of BAX/BCL2Clinical Implication: This means that the genesare now fighting cancer by enhancing apoptosis.


65/122

BSW (c) 2010


10) Reduces Estrogen LevelsClinical Implication: This is an anti-cancer effect

since it also reduces ER-a.

11) Increases Estrogen receptor-beta receptorsClinical Implication: These kill cancers by

increasing the amount of natural chemotoxic

agents like 2-methoxyestradiol as well as theirdelivery to the cancer cell.


66/122

BSW (c) 2010


12) Decreases Estrogen receptor-alpha receptors ER-a

Clinical Implication: These receptors allow cancercells to thrive and metastasize so they must besuppressed for your health.

13) Improves Ratio- ER-a/ER-b

Clinical Implication: This allows for appropriateapoptosis and restoration of low cancer risk.


67/122

BSW (c) 2010


14) Decreases the matrix metalloproteinases enzymeClinical Implication: This enzyme erodes collagen

surrounding the tumor and frees cancer stem cellsto spread through out the body creating metastaticdisease.

15) Produces Anti-Cancer metabolites

Clinical Implication: Some of the most important of these are 3-Beta Adiol and 2-methoxyestradiolwhich hunt down and kill cancer stem cells.


68/122

BSW (c) 2010


16) Prevents Protein Calorie Malnutrition(cachexia or starvation)

Clinical Implication: This reversal of cachexiais life-saving since cachexia kills 80% of cancer patients. We must at all costs avoidthe situation where you starve (no appetite!)

while the cancer gorges itself.


69/122

BSW (c) 2010


17) Decreases Viral and Bacterial BurdensClinical Implication: Haelan 951 cleans house

and allows the immune system to work

without distraction.

18) Increases function of GADPH gene

expressionClinical Implication: This gene expression isone way to measure cancer die off.


70/122

BSW (c) 2010


19) Shuts Down NF-kB Mutation PathwayClinical Implication: Cancer cells are smart and

they try to mutate using the NF-kB pathway inorder to escape death when the immune system orthe chemotherapy is applied.

20) Enhances tumor necrosis factor (TNF)

Clinical Implication: TNF is a pillar of our immunesystem required to fight cancer.


71/122

BSW (c) 2010


21) Non-Specific Immune Stimulation Increased400%

Clinical Implication: the symbiosis of taking aproduct offering the 5 super foods (Haelan 951)and the myriad benefits described above amountto a huge immune boost. It increases macrophagephagocytosis by three-fold and double thenumber of active macrophages.


72/122

BSW (c) 2010


22) Gives clearer margins for surgical removal of tumors

Clinical Implication: If surgery is indicated, the goalis 1) to remove the cancerous cells and 2) to cut

away leaving a clean margin meaning leaving noresidual cells.

23) Overcomes depression and improves quality of

lifeClinical Implication: When the soul and spirit areless troubled, the immune system thrives.


73/122

BSW (c) 2010

Curcumin, the yellow pigment found inthe spice turmeric and a key ingredientin yellow curry inhibits melanoma cellgrowth and stimulates tumor cell death

via apoptosis

potent antioxidant, anti -inflammatoryand cancer terminating effects

CANCER August 15, 2005


74/122

BSW (c) 2010

Proteolytic Enzymes (away from food):

1) selectively attack and kill cancer cells2) clean up after themselves (debris)

3) unmask cancer cells ( membrane effect)4) prevent metastatic disease5) offer systemic immune enhancement

6) compelling scientific /clinical record7) excellent risk/benefit ratio

VITAMIN D3


75/122

BSW (c) 2010

VITAMIN D3

A preponderance of evidence from the bestobservational studies... has led to the conclusion thatpublic health action is needed.

Primary prevention of these cancers has beenlargely neglected, but we now have proof that theincidence of colon, breast and ovarian cancer can bereduced dramatically by increasing the public's

intake of vitamin D."Professor Cedric Garland the University of San Diego, Californiaafter reviewing 63 recent studies on vitamin D and cancer.


76/122

BSW (c) 2010

Vitamin C plus Vitamin K3

1. Vitamin K3 alone has demonstrated anti-tumoractivity against multiple rodent and humancancer cell lines.

2. Synergism noted with doxorubicin, 5 FU,vinblastine, vincristine, mitomycin, bleomycin,cisplatin, mitoxanthrone, MTX, and manyothers.

3. Phase I trials in humans 400-500 mg/day showedno toxicity in combination with mitomycin.Phase II trials of IV K3 (2.5 gms/m2) withmitomycin showed objective response but 30%showed hemolysis (Gold, Cancer Treat Rep, 1986)


77/122

BSW (c) 2010

Vitamin C Plus Vitamin K3 contd

1) Vit C and K3 combination showed synergisticactivity in a 100/1 ratio in breast, endometrialand oral epidermoid carcinoma cell lines inconcentrations 10-50 times lower than for theindividual vitamins (Noto, et al, Cancer, 1989).

2) Co administration of C plus K3 with adriamycin,

bleomycin, mitomycin C, vincristine or cisplatinincreased growth inhibitory effect by 3-14 fold(Buc Calderone, et al., Curr. Med. Chem. 2002).


78/122

BSW (c) 2010

Vit C and K3: The Mechanism of Action

High levels act via oxidative stress and arecytotoxic via necrosis or autoschizis.

Low levels kill by a non-oxidative mechanisminvolving transcription factors to produceautochizis and apoptosis.


79/122

BSW (c) 2010

Vitamin C: Cancers silver bullet

1. Vitamin C alone has been found to have cytotoxic effectsagainst most cancer cell lines in vitro. These in vitroconcentrations are easily achievable in vivo with IV C.The mechanism appears to be intracellular accumulationof H2O2 with low catalase enzyme activity native to

cancer cells. (Dr. Mark Levine, NIH division of Diabetes andKidney diseases).

2. Vit C has also been found to potentiate the effects of chemotherapy drugs (Zaizen, et al., J cancer Res Lin Oncol,1986; Prasad, et al, Pol J Pharmacol and Pharm, 1992; Koch andBiaglow, J Cell Physiol, 1978) and radiation therapy (Hanck, ProgClin Biol Res, 1988).

Oxygen breathing may be a cheaper and safer alternative to


80/122

BSW (c) 2010

exogenous erythropoietin (EPO)

Recently discovered normobaric oxygen paradox demonstratesthat renal tissue can be stimulated to increase EPO production via a

simple pattern of oxygen breathing at normal atmosphericpressures. This leads directly to the hypothesis that oxygen

breathing may provide chemotherapy patients with a convenient andinexpensive alternative to ESAs. Stimulating endogenous EPO

production eliminates the small risk of immune system reactionassociated with ESAs. Further, the endogenous physiological EPO

doses provided by this method may be safer, in terms of cancer

mortality, than the exogenous pharmacological doses inherent inESA administration.

Author: R. Burk Medical Hypothesis published on line 5/ 11/ 07

S ifi i i l l i IV


81/122

BSW (c) 2010

Specific nutritional supplements given IVafter insulin but before therapeutic moment

Resveratrol Quercetin

Theanine Proline

Glutamine Arginine

Acetyl-L -carnitine Niacinamide

Artemisinin N- Acetyl Cysteine


82/122

BSW (c) 2010

Exercise

ActivityDoing justice to what comes inProcessingDigestingExpression

Creativity (our birthright!)


83/122

BSW (c) 2010

Thought

CorThotThoughts create feelingFeelings are transientThoughts are directableReason for living

Quality of life


84/122

BSW (c) 2010

Case#1: Hodgkins Lymphoma stage IV

65 year old male, otherwise healthyLump on neck no other symptomsPET results February 2010: Multiple areas of

abnormal metabolic activity seen in head and neck.Abnormal metabolic activity seen along retroaorticthoracic lymph node. L3-L4 skeletal lesions.Impression: stage IV Hodgkins lymphoma withmultiple stations of adenopathy in head and neck,chest, abdomen and pelvis.


85/122

BSW (c) 2010

Proposed Treatment

Meds: Bleomycin

Assurance: Dont worry. We have anexcellent success rate with HodgkinsLymphoma: 6 months of Hell and then 2 yearsof recovery, but after that, you will be cancer

free.


86/122

BSW (c) 2010

Conventional Treatment Course

2 treatments of conventional chemotherapy:Vinblastine, Cytoxan, Adriamycin,Prednisone, Procarbazine, Omeprazole,

ProchlorperazineSide effects: nausea,Never again. Id rather die.


87/122

BSW (c) 2010

CCC starting April 2010

1) IPT chemotherapy: Bleomycin 1 unit, Adriamycin 6mg,Dacarbazine 20mg, Vinblastine 1mg.2) HDVC: 50g /450cc sterile water w/ 2cc Magnesium SO43) Alpha Lipoic Acid 600mg in 50cc nl saline4) Homeopathics:

Au Stibium Hyoscyamus Hepar Stannum 6/10Lien Cichorium Lymphocytes 8Thrombocytes 6 Erythrocytes 6

Oral Supplements: Haelan 951, MVMM, Niacin, Selenium,CoQ 10, vitamin D3, LDN 4.5mg


88/122

BSW (c) 2010

Clinical Progress

PET/CT 4-14- 10: IMPRESSION: remarkableimprovement since 2-2-10 with near completeresponse. Oncologist: My treatment has kicked in.

Patient goers off protocol: alcohol, sugarPET/CT 6-11- 10: enlarged nodes on both sidesof the neck, supraclavicular space and themediastinum, retrocrural lymph nodes, skeletallesions at L3 L4. Disease progression seencompared to 2-2-10 PET/CT. Patient leapt back on CCC protocol.


89/122

BSW (c) 2010

PET: 8/6/10

Head and Neck no evidence of adenopathyno focal lesions to suggest recurrence in the headand neck. Chest no abnormal metabolic activity seen in

nodes no new lesions no suspiciouspulmonary nodes Abdomen: no organomegaly, no adenopathy Skeleton: No focal suspicious lytic or blasticskeletal lesions seen. Impression: No PET CT evidence for residualor recurrent lymphoma.


90/122

BSW (c) 2010

Case #2: Leiomyosarcoma (uterine)


91/122

BSW (c) 2010

Case #2: Leiomyosarcoma (uterine)stage IV with mets to Lung

51 yr old woman, onset age 47Failed surgery, chemotherapy, and radiation.Gemzar & Taxotere, Adriamycin & Cis Platin, Ifosfamide& Mesna & Adriamycin, Gemzar & Taxotere,Dacarbazine, Yondelis trialPET/ CAT Jan 2010 Innumerable metastatic pulmonarylesions aggressive disease.Tumor markers Jan 2010 CA 125=173, CA 19-9 =70I am shocked it came back so quickly. Put your affairs in orderSeattle oncologist refused more care

CCC i M h 2010


92/122

BSW (c) 2010

CCC starting March 2010

1) IPT: Cytoxan 150mg, Gemzar 200mg, Methotrexate 12.5mg2) HDVC: 50g /450cc sterile water w/ magnesium SO43) Alpha Lipoic Acid 600mg in 50cc nl saline

4) Homeopathics:Au Stibium Hyoscyamus Hepar Stannum 6/10Lien Cichorium Lymphocytes 8Thrombocytes 6 Erythrocytes 6

Oral Supplements: Haelan 951, MVMM, Niacin,Selenium, CoQ 10, vitamin D3, LDN 4.5mg

R di hi P


93/122

BSW (c) 2010

Radiographic Progress

PET/CAT April 2010: The innumerablebilateral pulmonary metastatic lesions have shownsubstantial decrease in size and number. None of these lesions shows a significant degree of

metabolic activity. Abdomen/pelvis: stable, noevidence of local recurrence of metastatic disease.

PET/CAT July 2010: Essentially all of thepreexisting metastases are smaller and/or lessdense of current exam. No new lung metastasis.

T M k


94/122

BSW (c) 2010

Tumor Markers

DATE CA 125 CA 19-9

January 2010 138 41

March 2010 53 33

June 2010 18 49

September 2010 15 35


95/122

BSW (c) 2010

Case #3 Fallopian tube cancer


96/122

BSW (c) 2010

pwith mets to Lung

67 yr old woman s/p breast cancer 1994(mastectomy with adjuvant chemotherapy andTamoxifen) then fallopian tube cancer 2000 thenrecurrence with mets to lung 2008.Tumor Markers 6/10:

CA 125 = 8883 CA 19-9 = 98PET/CT 5-29- 10: Interval worseningpersistent abnormal uptake, persistenthypermetabolic adenopathy

CCC t ti J 2010


97/122

BSW (c) 2010

CCC starting June 2010

1) IPT Chemotherapy drugs: Cisplatin 5-10mg vs.Carboplatin 25-50mg, with Gemzar 50-100-200mg,

2) HDVC: 50g /450cc sterile water w/ magnesium SO43) Alpha Lipoic Acid 600mg in 50cc nl saline

4) Homeopathics:Au Stibium Hyoscyamus Hepar Stannum 6/10Lien Cichorium Lymphocytes 8Thrombocytes 6 Erythrocytes 6

Oral Supplements: Haelan 951, MVMM, Niacin, Selenium,CoQ 10, vitamin D3, LDN 4.5mg

T M k


98/122

BSW (c) 2010

Tumor Markers

DATE CA 125 CA 19-9

June 8883 98

July 3249 92

August 1314 60

September 873 40


99/122

BSW (c) 2010

The original Come Hither look.

C #4 C l t l Ad i


100/122

BSW (c) 2010

Case #4 Colorectal Adenocarcinoma

Nov 2006 A 65 yr old man noted a mass protrudingfrom anus and blood in stool. Thought it washemorrhoids so did nothing for 11 months!

October 2007 doctor does a DRE and notes large massDx from Bx: Stage IV Colorectal Adenocarcinoma

December 2007 CAT rectal mass and liver met 7mm

March 2008 Pt. refused chemo, took radiation (28rounds of external beam) and Arimidex. Doing lotsof nutritional supplements. Comes for IPT.

C 3 C l t l CA td


101/122

BSW (c) 2010

Case 3 Colorectal CA contd

CEA 12.3 on 10-22-07He was started on alternating IPT regimen 2X/wk5-FU 250mg, Mitomycin 2mg, Leukovorin 10mg 50 c cnl saline SIVP before the 5-

FU in , IM Intron rectal ozone insuflationalternate with5-FU 250mg, Leukovorin 10mg in 50 cc nl saline with Irinotecan 20mg/cc

orOxaliplatin 10mg with Ribavarin 200mg rectal ozone insuflation

On 12-03-07 CEA 19.8 ng/ml (nl


102/122

BSW (c) 2010

IPT: alternating IPT regimen 2X/wk:1) 5-FU 250mg, Mitomycin 2mg, Leukovorin 10mg 50

cc nl saline SIVP before the 5-FUalternate with

2) 5-FU 250mg, Leukovorin 10mg in 50 cc nl salinewith Irinotecan 20mg/cc

or

3) Oxaliplatin 10mg with Ribavarin 200mg

With Intron IM and rectal ozone insuflation

The rest is standard


103/122

BSW (c) 2010

The rest is standard

2) HDVC: 50g /450cc sterile H2O w/ mag SO4 2 cc3) Alpha Lipoic Acid 600mg in 50cc nl saline4) Homeopathics:

Au Stibium Hyoscyamus Hepar Stannum 6/10Lien Cichorium Lymphocytes 8Thrombocytes 6 Erythrocytes 6

Oral Supplements: Haelan 951, MVMM, Niacin,Selenium, CoQ 10, vitamin D3, LDN 4.5mg


104/122

BSW (c) 2010

CEA REPORTS

Date Results10/22/07 12.312/03/07 19.812/26/07 16.9

01/07/08 15.604/09/08 1.607/09/08 Less than 0.510/19/08 Less than 0.501/21/10, 4/21/10, 7/21/10 - all Less than 0.5The oral chemotherapy chlorine dioxide started 12/14/07.Radiation therapy February through March 2008.Surgery to remove the cancer May 9th of 2008.

November 3 2008


105/122

BSW (c) 2010

November 3, 2008

Dear Dr. Weeks,

Attached is a record of my CEA results correlated withtreatment modalities. IPT was very effective with no side-effects and allowed my surgery to be minimal and now I feelfine.

I have been keeping track of the billings for conventionaltreatments. The total for surgery and radiation treatment is in

excess of $150,000 but I do not have an exact figure. If I hadaccepted the chemotherapy that was repeatedly thrust uponme the bill would have been considerably higher. I am gratefulto you and the pioneers who are practicing IPT.

2010 Follow up of Case 3


106/122

BSW (c) 2010

2010 Follow-up of Case 3

Dear Brad, It is good to hear from you.My health continues to be good and,

considering all of the surgery, my energyand ability to function and work are good.My emotional health and sense of wellbeing

are also good. IPT was a life saver.

For health maintenance I take a daily dose of


107/122

BSW (c) 2010

seawater mineral extract that I make, a tablespoonof wheat germ oil and 1,000 mg of vitamin C.

On every day that the sun does not shine I take10,000 IU of vitamin D-3. About once each week I

take an Iodoral tablet. Each night before bed I take

a 3 mg tablet of melatonin and 1.25 oz of rum.Once every 60 days I take San Pedro cactus extract.

At the first sign of any serious physical problem I

would not hesitate to began a course of MMStreatment. Have you noticed that MMS has nowbeen suppressed by the FDA?


108/122

BSW (c) 2010

2) Antioxidants and immune enhancing protocols dot i t f ith IPT b t th h b fit


109/122

BSW (c) 2010

not interfere with IPT but rather enhance benefitand are protective of healthy cells and vitality.

3) Patients find the experience not unpleasant (asidefrom the therapeutic moment of low blood sugar).

4) Side-effect free effective chemotherapy is here!

S


110/122

BSW (c) 2010

Summaryand

Invitation

Corrective Cancer Care

with Insulin Potentiation Therapy


111/122

BSW (c) 2010

The Standard of Care is sub-therapeutic.

Only 10% of conventional oncologists

say they would take the medication theyprescribe if they had cancer.

In contrast, 100% of IPT doctors wouldtake their own medicine!


112/122

BSW (c) 2010

"I die by the help of too many physicians."

Alexander the Greaton his deathbed, 323 B.C.

Corrective Cancer Care with IPT


113/122

BSW (c) 2010

SafeEffectiveCost-effective

and

The longest continuous cancerchemotherapeutic protocol in thewestern hemisphere (1926-present)

Corrective Cancer Care with IPT cont


114/122

BSW (c) 2010

Corrective Cancer Care with IPT cont.

Smart Bomb effect: Excess of insulin-sensitive receptors on human cancercells causes predominance of insulin

effect in cancer cells, sparing normalhost tissues = INCREASED SAFETY

Synergy of insulins membrane and metaboliceffects enhances anticancer drug action incancer cells = INCREASED EFFICACY

Wh ff b d th t d d


115/122

BSW (c) 2010

Why we offer beyond the standard

of care therapies?

1) more effective treatment2) more grateful patients3) more personal and professional

satisfaction

Quality of Life


116/122

BSW (c) 2010

Quality of Life

1) Appreciate all things at all times2) Laugh and cry3) Be Curious and allow surprises4) Participate (walk the dog!)

and5) Appreciate all over again!


117/122

BSW (c) 2010

Rory reminding us to take the time

to stop and smell the flowers!


118/122

BSW (c) 2010

Dear Dr. Weeks,After my amazing treatments at

your wonderful clinic, I feel

so fantastic that I thinkI can walk on water.

But I know that you can!


119/122

BSW (c) 2010

We all can walk on water.It is only a matter of motivation .


120/122

BSW (c) 2010

WELCOME TO VISIT US IN SEATTLE !


121/122

BSW (c) 2010

Walking on Ebbys Landing Whidbey Island, with Rory.


122/122

IPT, Vitamin C and QOL

Documents

Transcript of IPT, Vitamin C and QOL